



Elenco Poster Discussion

ID	N. pgm	Title	Presenting Author
Clinical HIV I			
278	PD 1	Impact of M184V resistance mutation on virological efficacy of lamivudine-based dual therapies: an Italian ARCA cohort study	Roberta Gagliardini, Roma
46	PD 2	Budget impact analysis of the simplification to ATV+r+3TC of ATV+r+2NRTI therapy in Italy, based on the ATLAS-M Trial results at 96 weeks	Umberto Restelli, Castellanza Va
371	PD 3	Efficacy, tolerability and pharmacokinetics of dual therapy based on dolutegravir (DTG) and darunavir/ritonavir (DRV/r) qd in the clinical setting	Micol Ferrara, Torino
276	PD 4	Prevalence of and risk factors for potential drug-drug interactions (PDDIs) between antiretroviral (ARV) and non-antiretroviral (non-ARV) medications in patients aged ≥50 years	Alice Ranzani, Milano
247	PD 5	Polypharmacy and cART in HIV pts: different levels of adherence	Angela Calamo, Bari
290	PD 6	Inflammation markers and low levels viremia: gender difference in ARV treated HIV-1 patients	Francesca Falasca, Roma
Clinical HIV II			
15	PD 7	Effect of aspirin therapy on Abacavir-associated platelet hyperreactivity in HIV-infected patients: a randomized, double-blind, placebo-controlled, cross-over study	Elisabetta Schiaroli, Perugia
266	PD 8	Evaluation of eGFR by cystatin C formulas in HIV-1-infected patients with a decreased eGFR, treated with dolutegravir, rilpivirine or cobicistat	Nadia Galizzi, Milano
142	PD 9	Cerebrospinal Fluid HIV RNA and Neurocognitive Deficits: Are Lumbar Punctures Needed in Impaired Subjects with Undetectable Plasma Viral Load?	Mattia Trunfio, Torino
146	PD 10	Neurocognitive impairment (NCI) and hypovitaminosis D in a large cohort of HIV-infected persons	Alessandra Vergori, Roma
64	PD 11	Joint effect of HPV-16 infection and multiple HPV Genotypes as a Risk Factor for Anal Grade Squamous Intraepithelial Lesions in HIV-1 Infected Males	Silvia Nozza, Milano
358	PD 12	Lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio predict survival in HIV-infected patients with non-Hodgkin lymphomas	Alessandra Bandera, Monza
Hepatitis			
268	PD 13	Sustained virological response in HCV patients treated with daclatasvir+sofosbuvir, with or without ribavirin: a multicenter, field-practice experience	Elena Salomoni, Firenze
65	PD 14	HCC development in a cohort of HCV patients treated with DAAs, mono or co-infected with HIV	Gianluca Cuomo, Modena
304	PD 15	Long-term Follow Up of HIV/HBV Co-infected Patients Treated with Different Antiviral Drugs	Massimiliano Carlin, Torino
173	PD 16	Treatment with SOF/VEL is well tolerated and results in high SVR12 in genotype 1-6 HCV infected patients with minimal fibrosis: a retrospective analysis of the ASTRAL clinical studies	Luchino Chessa, Cagliari
348	PD 17	Effect of direct-acting antivirals for HCV on lipid profile in HIV-HCV coinfecting patients	Matteo Rinaldi, Bologna
16	PD 18	Distribution of different HBV DNA forms in plasma and PBMCs of chronically infected patients	Barbara Rossetti, Siena
Immunology			
234	PD 19	Characterisation Microparticles NK cells derived from Progressor and Non Progressors HIV infected patients compared to Healthy Donors	Federica Bozzano, Genova
59	PD 20	Immunological predictors of successful and safe anti-rejection therapy in HIV+ patients who underwent liver transplantation	Erica Franceschini, Modena
67	PD 21	High CD4:CD8 ratio and length of treatment independently correlate to the HIV-DNA intracellular content in different subsets of CD4+ T cells from virologically suppressed HIV+ patients	Simone Pecorini, Modena
192	PD 22	Cytokines-lymphoid progenitors interplay in treated acute HIV infection	Veronica Bordoni, Roma
20	PD 23	Interleukin -21/microRNA-29 axis in natural resistance to HIV-1 infection	Paula Andrea Serna Ortega, Milano
66	PD 24	Alteration in the expression of inflammasome components AIM2, PYCARD and IL-1β in HIV-infected patients with low CD4/CD8 ratio	Simone Pecorini, Modena
Basic Science and clinical virology			
		Is transmitted drug resistance to integrase inhibitors becoming a concern in Italy? A new case report	Maria Santoro, Roma
308	PD 25	New drug combinations and latest prescription guidelines are associated with a decrease in acquired resistance to antiretrovirals overtime	Alessia Lai, Milano
52	PD 26	Impact of the HIV-1 integrase natural polymorphism E157Q on susceptibility to integrase inhibitors	Francesco Saladini, Siena
320	PD 27	Analysis of HIV DNA levels in HIV positive patients treated with dolutegravir-containing regimen	Daniele Di Carlo, Roma
271	PD 28	Effect of exogenous interferon alpha on HIV viral populations in vivo	Giorgio Bozzi, Milano
233	PD 29	Is the management of HIV-1 drug-resistance still a clinical concern? A large Italian real life update in the modern antiretroviral era	Daniele Armenia, Roma
410	PD 30	HIV genotypic resistance test in Italy: difficulties in application and their impact in clinical practice	Sergio Lo Caputo, Bari



Elenco Poster Discussion

ID	N. pgm	Title	Presenting Author
Community			
361	PD 31	The new anti HCV oral Inteferon-free drugs (DAA) and the Drug-Drug Interactions (DDIs): data from a multi-center cohort of HCV monoinfected and HIV co-infected patients (DAADDI 2 study)	Benedetto Maurizio Celesia, Catania
71	PD 32	Preliminary Italian results in the COBA Cohort study, a pan-European cohort of HIV negative MSM enrolled in community-based voluntary counselling and testing services	Maria Luisa Cosmaro, Milano
401	PD 33	Physical activity is associated with frailty levels in HIV patients	Andrea Malagoli, Modena
136	PD 34	HIV test in an associaton. An opportunity of risk behaviour screening and use of chem	Alessandra Bianchi, Milano
38	PD 35	Clinical needs of PLWHA: how are they changing?	Franco Maggiolo, Landriano
249	PD 36	Complexity and transmission dynamics of the HIV-1 epidemic in Italy are influenced by transgender sex workers	Alessia Lai, Milano